CL2017002669A1 - Un análogo de quinolina trifluoroetil específico para uso en el tratamiento del síndrome de sjögren - Google Patents

Un análogo de quinolina trifluoroetil específico para uso en el tratamiento del síndrome de sjögren

Info

Publication number
CL2017002669A1
CL2017002669A1 CL2017002669A CL2017002669A CL2017002669A1 CL 2017002669 A1 CL2017002669 A1 CL 2017002669A1 CL 2017002669 A CL2017002669 A CL 2017002669A CL 2017002669 A CL2017002669 A CL 2017002669A CL 2017002669 A1 CL2017002669 A1 CL 2017002669A1
Authority
CL
Chile
Prior art keywords
sjögren
trifluoroethyl
syndrome
treatment
analog
Prior art date
Application number
CL2017002669A
Other languages
English (en)
Inventor
Rodger Anthony Allen
Francesca Barone
William Anthony Fahy
Saba Nayar
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2017002669A1 publication Critical patent/CL2017002669A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>N-{(R)-1 -[8-Cloro-2-(1 -oxipiridin-3-il)-quirtolin-3-il]-2,2,2-trifluoroetil}-pirido[3,2-d]pirimidin-4- ¡lamina es efectivo en el tratamiento y/o prevención de Sindrome de Sjögren.</p>
CL2017002669A 2015-04-21 2017-10-20 Un análogo de quinolina trifluoroetil específico para uso en el tratamiento del síndrome de sjögren CL2017002669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use

Publications (1)

Publication Number Publication Date
CL2017002669A1 true CL2017002669A1 (es) 2018-05-11

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002669A CL2017002669A1 (es) 2015-04-21 2017-10-20 Un análogo de quinolina trifluoroetil específico para uso en el tratamiento del síndrome de sjögren

Country Status (27)

Country Link
US (1) US10493074B2 (es)
EP (1) EP3285772B1 (es)
JP (1) JP6721606B2 (es)
KR (1) KR102627370B1 (es)
CN (1) CN107530344B (es)
AR (1) AR105552A1 (es)
AU (1) AU2016251236B2 (es)
BR (1) BR112017020591B8 (es)
CA (1) CA2981631C (es)
CL (1) CL2017002669A1 (es)
CO (1) CO2017010573A2 (es)
CY (1) CY1122572T1 (es)
DK (1) DK3285772T3 (es)
EA (1) EA032432B1 (es)
ES (1) ES2763335T3 (es)
GB (1) GB201506786D0 (es)
HR (1) HRP20192273T1 (es)
HU (1) HUE047162T2 (es)
IL (1) IL254766B (es)
LT (1) LT3285772T (es)
MX (1) MX2017013148A (es)
MY (1) MY192972A (es)
PL (1) PL3285772T3 (es)
PT (1) PT3285772T (es)
SG (1) SG11201707789YA (es)
SI (1) SI3285772T1 (es)
WO (1) WO2016170014A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005245875C1 (en) * 2004-05-13 2017-08-31 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
JP5527761B2 (ja) * 2007-03-23 2014-06-25 アムジエン・インコーポレーテツド 複素環化合物およびそれの使用
PL2496567T3 (pl) * 2009-11-05 2018-01-31 Rhizen Pharmaceuticals S A Nowe benzopiranowe modulatory kinazy
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR082799A1 (es) 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
BR112015031475A2 (pt) * 2013-06-14 2017-07-25 Gilead Sciences Inc composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.

Also Published As

Publication number Publication date
BR112017020591B8 (pt) 2023-05-16
JP6721606B2 (ja) 2020-07-15
IL254766A0 (en) 2017-12-31
AU2016251236B2 (en) 2018-06-14
SG11201707789YA (en) 2017-11-29
EA032432B1 (ru) 2019-05-31
AU2016251236A1 (en) 2017-11-09
PL3285772T3 (pl) 2020-05-18
GB201506786D0 (en) 2015-06-03
US20180092921A1 (en) 2018-04-05
CA2981631A1 (en) 2016-10-27
LT3285772T (lt) 2020-01-10
MY192972A (en) 2022-09-20
US10493074B2 (en) 2019-12-03
CN107530344B (zh) 2020-03-17
CN107530344A (zh) 2018-01-02
HUE047162T2 (hu) 2020-04-28
KR20170140245A (ko) 2017-12-20
EP3285772B1 (en) 2019-10-02
CO2017010573A2 (es) 2018-03-09
IL254766B (en) 2020-05-31
SI3285772T1 (sl) 2020-02-28
JP2018513862A (ja) 2018-05-31
MX2017013148A (es) 2018-02-21
DK3285772T3 (da) 2020-01-13
WO2016170014A1 (en) 2016-10-27
CA2981631C (en) 2023-02-21
KR102627370B1 (ko) 2024-01-18
EP3285772A1 (en) 2018-02-28
EA201792318A1 (ru) 2018-05-31
BR112017020591A2 (pt) 2018-07-03
HRP20192273T1 (hr) 2020-03-06
BR112017020591B1 (pt) 2023-02-07
CY1122572T1 (el) 2021-01-27
AR105552A1 (es) 2017-10-18
PT3285772T (pt) 2020-01-14
ES2763335T3 (es) 2020-05-28

Similar Documents

Publication Publication Date Title
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
PH12017501780A1 (en) Maytansinoid derivatives, conjugates thereof, and methods of use
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
IL289975A (en) Use of cannabidiol in the treatment of Derva syndrome
CO2018013559A2 (es) Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds)
CL2015002897A1 (es) Inhibidores de bace1
DK4005570T3 (da) Pridopidin til anvendelse behandling af retts syndroe
SG10202013034QA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
DK3463436T3 (da) Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
EP3533451A4 (en) APPLICATION OF PAEENIFLORIN-6&#39;-O-BENZENE SULFONATE IN MEDICINE FOR THE TREATMENT OF SJÖGREN SYNDROME
CL2017002669A1 (es) Un análogo de quinolina trifluoroetil específico para uso en el tratamiento del síndrome de sjögren
WO2015102000A3 (en) Ophthalmic viscosurgical device
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL282142A (en) The history of 4-pyrazine-2-ylmethyl-morpholine and its use as a medicine
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
GB2569682B (en) Topical composition for use in the treatment of burns
IT201700109607A1 (it) Composizione per l&#39;uso nella prevenzione e/o nel trattamento del glaucoma.
CL2018001871A1 (es) Uso de inhibidores de la actividad o función de pi3k para el tratamiento del síndrome de sjögren primario
IL271258A (en) Use of mavoglurant in reducing alcohol use or preventing a return to alcohol use
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі